Akari Therapeutics (NASDAQ:AKTX – Get Free Report) and BioHarvest Sciences (NASDAQ:BHST – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability.
Profitability
This table compares Akari Therapeutics and BioHarvest Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Akari Therapeutics | N/A | -68.38% | -31.89% |
| BioHarvest Sciences | -36.33% | -1,041.86% | -36.06% |
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Akari Therapeutics and BioHarvest Sciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Akari Therapeutics | 1 | 0 | 3 | 0 | 2.50 |
| BioHarvest Sciences | 1 | 0 | 3 | 0 | 2.50 |
Valuation & Earnings
This table compares Akari Therapeutics and BioHarvest Sciences”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Akari Therapeutics | N/A | N/A | -$19.79 million | N/A | N/A |
| BioHarvest Sciences | $25.19 million | 3.00 | -$12.91 million | ($0.68) | -6.76 |
BioHarvest Sciences has higher revenue and earnings than Akari Therapeutics.
Institutional and Insider Ownership
5.1% of Akari Therapeutics shares are held by institutional investors. 30.7% of Akari Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Risk & Volatility
Akari Therapeutics has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500. Comparatively, BioHarvest Sciences has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500.
Summary
Akari Therapeutics beats BioHarvest Sciences on 6 of the 9 factors compared between the two stocks.
About Akari Therapeutics
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.
About BioHarvest Sciences
BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
